What is the Origin of Combined MHT?

The practice of MHT, formerly known as HRT, arose from the clinical need to alleviate debilitating vasomotor and urogenital symptoms associated with estrogen deficiency post-menopause. The addition of progestogen became standard protocol following the recognition of the increased risk of uterine cancer with estrogen-only therapy in women with an intact uterus. This combination reflects an evolution in clinical understanding of hormonal safety and efficacy.

What is the Mechanism of Combined MHT?

The estrogen component acts by binding to estrogen receptors throughout the body, alleviating symptoms like hot flashes, sleep disturbances, and vaginal atrophy, while also providing beneficial effects on bone density. The progestogen component acts on the endometrial lining, inducing secretory changes and preventing the proliferative effects of estrogen, thereby offering uterine protection. This dual mechanism ensures systemic relief while minimizing specific organ risks, achieving a therapeutic balance.

Combined MHT ∞ Area

Combined MHT

Meaning

Combined Menopausal Hormone Therapy (Combined MHT) is a pharmacological regimen prescribed to manage menopausal symptoms, consisting of both an estrogen and a progestogen component. This therapeutic approach is typically indicated for individuals who still possess a uterus, as the progestogen is included specifically to mitigate the risk of endometrial hyperplasia and carcinoma associated with unopposed estrogen. It is a cornerstone of modern hormone management, offering systemic relief while providing uterine protection.